Results
1 -
10 of
66Pharmacokinetic data on beta-adrenoceptor antagonists, Handbook of Clinical Pharmacokinetic Data Quality of Life Assessments in Clinical Trials of Angina Pectoris, Drug Evaluation in Angina Pectoris The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease, European Journal of Clinical Pharmacology The influence of beta-adrenoceptor antagonists with and without partial agonist activity on exercise tolerance and muscle lactate production, European Journal of Clinical Pharmacology Do partial agonist beta-blockers have improved clinical utility?, Cardiovascular Drugs and Therapy Modest antihypertensive effect of epanolol, a beta1-selective receptor blocker with beta1 agonist activity: An acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure, Cardiovascular Drugs and Therapy Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease, Cardiovascular Drugs and Therapy Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: Review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin, Cardiovascular Drugs and Therapy Epanolol: has less antihypertensive effect than pindolol and apparently possesses dose-related intrinsic sympathomimetic activity, InPharma Patient Preference in Antianginal Therapy, InPharma